Licensing, funding, and IPO activity support sector development

许可、资金和首次公开募股活动支持行业发展

South Korea

韩国

's biopharma companies have secured about $4.2b in biologics licensing agreements, reflecting increased activity in advanced modalities including antibody–drug conjugates and cell and gene therapies, according to McKinsey & Company.

根据麦肯锡公司的数据，生物制药公司已经获得了大约42亿美元的生物制品许可协议，这反映了包括抗体药物偶联物以及细胞和基因疗法在内的先进模式的活动增加。

Transactions include GlaxoSmithKline’s $2.5b agreement with ABL Bio to develop therapies designed to cross the blood–brain barrier for neurodegenerative diseases, alongside LigaChem Biosciences’ $1.7b partnership with J&J Innovative Medicine. McKinsey said the deals indicate broader participation by South Korean firms in global oncology and next-generation therapeutic development..

交易包括葛兰素史克与ABL Bio达成的25亿美元协议，以开发穿越血脑屏障、针对神经退行性疾病的疗法，以及LigaChem Biosciences与强生创新制药17亿美元的合作。麦肯锡表示，这些交易表明韩国企业在肿瘤学和下一代治疗开发领域的全球参与更加广泛。

South Korean companies are also increasing involvement in global regulatory filings and multiregional clinical trials. This activity is supported by hospital-linked research centres and an expanding base of contract development and manufacturing organisations, the report said.

韩国公司也越来越多地参与全球监管文件和多地区临床试验。报告称，这项活动得到了医院相关研究中心以及不断扩大的合同开发和制造组织的支持。

Public funding has contributed to sector expansion. Biopharma has been designated one of 55 National Strategic Technologies, and the Korea Drug Development Fund has committed $2b to support more than 1,200 innovation projects through 2030, according to McKinsey.

公共资金促进了该行业的扩张。根据麦肯锡的报告，生物制药已被指定为55个国家战略技术之一，韩国药物开发基金已承诺投入20亿美元，到2030年支持超过1200个创新项目。

Capital markets have provided additional financing channels, with about 40 biotech initial public offerings on the KOSDAQ since 2018, including listings by pre-revenue companies. McKinsey said these factors together support continued development of South Korea’s biopharma sector.

资本市场提供了更多的融资渠道，自2018年以来，约有40家生物技术公司在科斯达克（KOSDAQ）进行了首次公开募股（IPO），其中包括一些尚未实现收入的公司。麦肯锡表示，这些因素共同支持了韩国生物制药行业的持续发展。